What is AbbVie's SG&A?

AbbVie (ABBV) reported SG&A of $3.58B in Q1 2026.

How has AbbVie's SG&A changed year-over-year?

AbbVie's SG&A increased by 8.7% year-over-year, from $3.29B to $3.58B.

What is the long-term trend for AbbVie's SG&A?

Over 4 years (2021 to 2025), AbbVie's SG&A has grown at a 3.2% compound annual growth rate (CAGR), from $12.35B to $14.01B.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

AbbVie ABBV SG&A

SG&A at other companies

Eli LillyLLY

$2.93B+18.9%

PfizerPFE

$2.96B-2.3%

Johnson & JohnsonJNJ

$6.03B+18.0%

AmgenAMGN

$1.6B-5.0%

The Cooper Companies, Inc.COO

$676.2M+69.5%

Cardinal HealthCAH

$1.54B+17.3%

Other financials

Income statement

See full

Revenue$15.0B+12.4%

Gross profit$10.8B+15.4%

Operating income$4.0B+6.9%

Net income$695.0M-46.0%

EPS (diluted)$0.39-45.8%

Balance sheet

See full

Cash & equivalents$9.4B+81.5%

Total debt$62.4B+1.8%

Total equity-$6.7B-569%

Total assets$136.46B+0.2%

Cash flow

See full

Operating cash flow$3.8B+134%

CapEx$265.0M+12.8%

Free cash flow$3.6B+155%

Valuation

See full

Market cap$429.58B+31.2%

P/E118.2×+40.2×

P/S6.8×+1.1×

Profitability

See full

Gross margin70.7%0.0pp

Operating margin24.4%—

Net margin5.8%-1.5pp

FCF margin31.8%+5.0pp

Returns & leverage

See full

Return on equity89%+32.7pp

Debt / equity46.6×+38.6×

Current ratio0.8×0.0×

Where this comes from

Reported directly by AbbVie in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbbVie's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is AbbVie's SG&A?: AbbVie (ABBV) reported SG&A of $3.58B in Q1 2026.
How has AbbVie's SG&A changed year-over-year?: AbbVie's SG&A increased by 8.7% year-over-year, from $3.29B to $3.58B.
What is the long-term trend for AbbVie's SG&A?: Over 4 years (2021 to 2025), AbbVie's SG&A has grown at a 3.2% compound annual growth rate (CAGR), from $12.35B to $14.01B.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.